Ligand ID: IVM


Drugbank ID:
DB00602
(Ivermectin)


Indication:
A broad-spectrum anti-parasite medication. It was first marketed under the name Stromectol® and used against worms (except tapeworms), but, in 2012, it was approved for the topical treatment of head lice infestations in patients 6 months of age and older, and marketed under the name Sklice™ as well. Ivermectin is mainly used in humans in the treatment of onchocerciasis, but is also effective against other worm infestations (such as strongyloidiasis, ascariasis, trichuriasis and enterobiasis).

Get human targets for IVM in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'IVM' AND SARS-RELATED PROTEINS ONLY

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		1qz8 POLYPROTEIN 1AB
(SARSr-CoV)		6 / 12
ALA B  30
LEU B  45
LEU B  94
ILE B  91
LEU B 103
LEU B 106
1.78A16.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		1uj1 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 11
GLU A 178
ASN A  84
HIS A 134
ILE A 106
LEU A  86
1.80A21.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1uk2 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 13
ILE B 106
ILE B 136
ILE B 200
THR B 292
PHE B 294
1.61A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1uk2 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 13
ILE A 106
ILE A 136
ILE A 200
THR A 292
PHE A 294
1.61A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1uk3 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.61A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1uk4 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.55A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1uk4 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.54A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		1wnc E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 10
ALA D 926
LEU D 930
GLN E1161
LEU E 930
ILE F1160
1.26A14.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		1wnc E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 10
VAL B1157
LEU F 930
GLN F1161
LEU E 927
ILE E1164
1.45A14.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1wnc E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
SER E 924
ASN E1168
ASP E1165
ILE E1164
THR D 925
1.48A17.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		1wnc E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 11
LEU E 920
ASN E1173
SER E 914
ILE E 913
LEU F 920
1.64A20.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1wnc E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 13
THR A 923
SER A 924
ASN A1168
ILE A1164
THR C 925
1.51A17.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1wnc E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 13
THR E 923
SER E 924
ASN E1168
ILE E1164
THR D 925
1.39A17.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1wnc E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 13
THR B 923
SER B 924
ASN B1168
ILE B1164
THR A 925
1.64A17.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1wnc E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 13
THR D 923
SER D 924
ASN D1168
ILE D1164
THR F 925
1.53A17.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1wnc E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 13
THR C 923
SER C 924
ASN C1168
ILE C1164
THR B 925
1.38A17.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		1wnc E2 GLYCOPROTEIN
(SARSr-CoV)		6 / 12
THR D 923
SER D 924
LEU E 927
LEU E 930
ILE D1160
LEU F 927
1.54A14.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1wnc E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 13
THR F 923
SER F 924
ASN F1168
ILE F1164
THR E 925
1.51A17.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		1wnc E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 11
LEU C 920
ASN C1173
SER C 914
ILE C 913
LEU A 920
1.64A20.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		1wnc E2 GLYCOPROTEIN
(SARSr-CoV)		6 / 10
THR D 923
VAL D 933
LEU E 927
GLN D 931
LEU F 927
ILE F1164
1.74A14.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1wof 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE B 106
ILE B 136
GLY B 109
THR B 292
PHE B 294
1.64A23.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1wof 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.55A23.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1wof 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.54A23.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1wof 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.53A23.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		1wyy E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 11
GLU B1169
ASN B1168
ASN A 937
ILE B 913
LEU B1167
1.79A20.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1x7q HLA, A-11
(Homo
sapiens)		5 / 12
GLY A 265
THR A 182
LEU A 215
GLN A 262
ILE A 213
1.51A21.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1x7q BETA-2-MICROGLOBULIN
HLA, A-11
(Homo
sapiens)		5 / 12
SER A  92
ILE B  35
ASP B  34
THR A  10
PHE A  22
1.62A21.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1x7q BETA-2-MICROGLOBULIN
(Homo
sapiens)		5 / 13
ILE B   7
PRO B   5
THR B  86
ASN B  83
ILE B  92
1.52A15.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1z1i 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.60A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		1z1i 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 11
LEU A 271
MET A 276
ASN A 277
ILE A 286
LEU A 205
1.73A21.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1z1i 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.61A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		1z1j 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 11
GLU B1178
ASN B1084
HIS B1134
ILE B1106
LEU B1086
1.79A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		1z1j 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 11
LEU B1271
MET B1276
ASN B1277
ILE B1286
LEU B1205
1.73A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
SER G  24
ASN L  20
ASP L  17
ILE L  16
THR K  25
1.60A12.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR C  23
SER C  24
VAL C  33
LEU E  27
LEU A  27
1.26A9.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		6 / 10
THR K  23
VAL K  33
LEU G  27
GLN K  31
LEU I  27
ILE H  16
1.79A9.51
None
None
None
NA  K 205 (-4.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 13
THR I  23
SER I  24
ASN H  20
ILE H  16
THR G  25
1.35A12.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 13
THR C  23
SER C  24
ASN B  20
ILE B  16
THR A  25
1.39A12.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
SER A  24
ASN F  20
ASP F  17
ILE F  16
THR E  25
1.63A12.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		6 / 10
THR A  23
VAL A  33
LEU C  27
GLN A  31
LEU E  27
ILE D  16
1.72A9.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
SER C  24
ASN B  20
ASP B  17
ILE B  16
THR A  25
1.51A12.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		6 / 10
THR G  23
VAL G  33
LEU I  27
GLN G  31
LEU K  27
ILE J  16
1.72A9.51
None
None
None
NA  G 208 (-4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 13
THR K  23
SER K  24
ASN J  20
ILE J  16
THR I  25
1.39A12.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR E  23
SER E  24
VAL E  33
LEU A  27
LEU C  27
1.26A9.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 13
THR G  23
SER G  24
ASN L  20
ILE L  16
THR K  25
1.43A12.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR K  23
SER K  24
VAL K  33
LEU G  27
LEU I  27
1.27A9.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 13
THR E  23
SER E  24
ASN D  20
ILE D  16
THR C  25
1.54A12.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 13
THR A  23
SER A  24
ASN F  20
ILE F  16
THR E  25
1.46A12.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		6 / 10
THR I  23
VAL I  33
LEU K  27
GLN I  31
LEU G  27
ILE L  16
1.77A9.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
SER I  24
ASN H  20
ASP H  17
ILE H  16
THR G  25
1.48A12.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR G  23
SER G  24
VAL G  33
LEU I  27
LEU K  27
1.25A9.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
SER K  24
ASN J  20
ASP J  17
ILE J  16
THR I  25
1.57A12.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 11
GLU G  18
LEU H  19
SER I  19
ILE I  16
LEU L  19
1.72A13.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ALA K  26
LEU K  30
LEU K  27
GLN L  13
LEU G  30
1.32A9.20
None
None
None
NA  G 208 ( 4.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
SER E  24
ASN D  20
ASP D  17
ILE D  16
THR C  25
1.65A12.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		6 / 10
THR C  23
VAL C  33
LEU E  27
GLN C  31
LEU A  27
ILE F  16
1.75A9.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR I  23
SER I  24
VAL I  33
LEU K  27
LEU G  27
1.25A9.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2a5k 3C-LIKE PEPTIDASE
(SARSr-CoV)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.56A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2a5k 3C-LIKE PEPTIDASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.56A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		2acf REPLICASE
POLYPROTEIN 1AB
(SARS-COV
Tor2)		6 / 12
SER D 262
VAL D 231
ALA D 306
LEU D 304
LEU D 270
ILE D 217
1.74A18.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		2acf REPLICASE
POLYPROTEIN 1AB
(SARS-COV
Tor2)		6 / 12
SER A 262
VAL A 231
ALA A 306
LEU A 304
LEU A 270
ILE A 217
1.75A18.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		2acf REPLICASE
POLYPROTEIN 1AB
(SARS-COV
Tor2)		6 / 12
SER B 262
VAL B 231
ALA B 306
LEU B 304
LEU B 270
ILE B 217
1.76A18.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		2ajf ACE2
(Homo
sapiens)		5 / 11
GLU B 181
MET B 474
HIS B 493
ARG B 169
SER B 170
1.50A16.12
None
None
None
CL  B1902 (-4.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		2ajf ACE2
(Homo
sapiens)		5 / 10
VAL A 573
LEU A 520
PRO A 583
LEU A 584
ILE A 446
1.44A19.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		2ajf ACE2
(Homo
sapiens)		6 / 12
SER B 257
ALA B 251
LEU B 281
LEU B 162
PRO B 263
LEU B 262
1.69A19.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		2ajf ACE2
(Homo
sapiens)		6 / 10
THR B 282
ALA B 443
LEU B 444
ILE B 436
PRO B 284
ILE B 291
1.72A19.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		2ajf ACE2
(Homo
sapiens)		6 / 12
SER A 257
ALA A 251
LEU A 281
LEU A 162
PRO A 263
LEU A 262
1.71A19.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		2ajf ACE2
(Homo
sapiens)		5 / 10
THR A 282
SER A 280
LEU A 278
LEU A 248
ILE A 256
1.46A19.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2ajf ACE2
(Homo
sapiens)		5 / 13
ILE A 307
THR A 371
ILE A 358
MET A 360
THR A 334
1.63A19.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2amd 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.51A23.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		2amd 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 11
GLU A 178
ASN A  84
HIS A 134
ILE A 106
LEU A  86
1.78A20.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2amd 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.50A23.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2amd 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.52A23.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2amq 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.53A23.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2amq 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.54A23.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2amq 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE B 106
ILE B 136
GLY B 109
THR B 292
PHE B 294
1.66A23.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2amq 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.55A23.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2beq SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
SER C 924
ASN E1169
ASP E1166
ILE E1165
THR B 925
1.50A7.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2beq SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
SER B 924
ASN D1169
ASP D1166
ILE D1165
THR A 925
1.53A7.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		2beq SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR B 923
SER B 924
VAL B 933
LEU C 927
LEU A 927
1.24A6.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2beq SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 13
THR A 923
SER A 924
ASN F1169
ILE F1165
THR C 925
1.55A7.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		2beq SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
LEU F1182
ASN E1176
SER B 914
ILE B 916
LEU D1182
1.58A16.56
None
None
ACE  B 913 ( 4.3A)
ACE  B 913 ( 3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		2beq SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 10
THR A 923
VAL A 933
LEU B 927
GLN A 931
LEU C 927
ILE E1165
1.78A7.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		2beq SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 10
THR B 923
VAL B 933
LEU C 927
GLN B 931
LEU A 927
ILE F1165
1.73A7.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2beq SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 13
THR B 923
SER B 924
ASN D1169
ILE D1165
THR A 925
1.37A7.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		2beq SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 10
THR C 923
VAL C 933
LEU A 927
GLN C 931
LEU B 927
ILE D1165
1.73A7.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2beq SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 13
THR C 923
SER C 924
ASN E1169
ILE E1165
THR B 925
1.35A7.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		2beq SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR C 923
SER C 924
VAL C 933
LEU A 927
LEU B 927
1.28A6.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		2beq SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
THR A 923
ALA F1172
LEU F1168
LEU F1179
ILE A 916
ILE C 916
1.60A7.31
None
None
None
None
None
ACE  C 913 ( 4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		2beq SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ALA A 926
LEU A 930
LEU A 927
GLN D1162
LEU B 930
1.32A6.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2bx4 3C-LIKE PROTEINASE
(SARS-COV
Sin2774)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.60A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2c3s 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.54A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2c3s 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 13
ILE A 106
ASN A 133
ILE A 136
THR A 292
PHE A 294
1.61A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2c3s 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.53A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2cjr NUCLEOCAPSID PROTEIN
(SARS-COV
TW1)		5 / 12
GLN B 295
ASP B 291
ILE B 293
GLY B 288
PHE A 316
1.66A15.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2cjr NUCLEOCAPSID PROTEIN
(SARS-COV
TW1)		5 / 12
ILE C 305
ASP C 289
ILE C 293
GLY C 288
PHE D 315
1.55A15.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2cjr NUCLEOCAPSID PROTEIN
(SARS-COV
TW1)		5 / 12
ILE F 305
ASP F 289
ILE F 293
GLY F 288
PHE E 315
1.62A15.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2cjr NUCLEOCAPSID PROTEIN
(SARS-COV
TW1)		5 / 12
ILE A 305
ASP A 289
ILE A 293
GLY A 288
PHE B 315
1.58A15.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		6 / 12
ALA H  58
LEU G  47
ILE G  46
ILE G  45
PRO G  44
LEU G  22
1.75A13.02
None
None
None
D10  H1099 ( 4.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		6 / 12
ALA A  58
LEU B  47
ILE B  46
ILE B  45
PRO B  44
LEU B  22
1.78A13.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		6 / 12
ALA B  58
LEU A  47
ILE A  46
ILE A  45
PRO A  44
LEU A  22
1.71A12.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		2dd8 IGG HEAVY CHAIN
(Homo
sapiens)		6 / 12
SER H  30
SER H  31
VAL H 102
ALA H  24
ILE H  34
PRO H  52
1.69A23.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2duc REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 13
ILE B 106
PRO B 108
ASN B 133
ILE B 136
THR B 292
1.63A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		2fe8 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		6 / 12
THR B 103
ARG B 141
VAL B 126
ALA B 120
LEU B 119
LEU B 133
1.65A20.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		2fe8 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
THR C 103
VAL C 126
ALA C 120
LEU C 119
LEU C 133
1.23A20.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2gib NUCLEOCAPSID PROTEIN
(SARSr-CoV)		5 / 12
ILE A 305
ASP A 289
ILE A 293
GLY A 288
PHE B 315
1.59A13.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2gt7 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.58A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2gt7 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.57A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2gt8 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.56A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2gt8 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.58A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2gt8 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.59A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2gtb 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.52A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2gtb 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.55A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2gtb 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.53A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2jzd REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
ILE A 608
PRO A 607
MET A 624
THR A 528
ILE A 549
1.41A15.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2jzd REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
ILE A 567
ILE A 573
GLY A 572
ILE A 549
PRO A 548
1.30A15.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2jzd REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
ILE A 608
MET A 624
THR A 528
SER A 634
ILE A 549
1.52A15.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2jzd REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 13
ILE A 608
MET A 624
THR A 528
SER A 634
ILE A 549
1.53A15.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2jzd REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 13
ILE A 608
PRO A 607
MET A 624
THR A 528
ILE A 549
1.40A15.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2jzd REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
ILE A 549
PRO A 548
ILE A 567
ILE A 573
GLY A 572
1.30A15.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2jze REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 13
ILE A 608
PRO A 607
MET A 624
THR A 528
ILE A 549
1.40A15.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2jze REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
ILE A 567
ILE A 573
GLY A 572
ILE A 549
PRO A 548
1.30A15.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2jze REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 13
ILE A 608
MET A 624
THR A 528
SER A 634
ILE A 549
1.52A15.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2jze REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
ILE A 608
PRO A 607
MET A 624
THR A 528
ILE A 549
1.40A15.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2jze REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
ILE A 608
MET A 624
THR A 528
SER A 634
ILE A 549
1.52A15.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2jze REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
ILE A 549
PRO A 548
ILE A 567
ILE A 573
GLY A 572
1.30A15.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2kqv NSP3
(SARSr-CoV)		5 / 12
ILE A  27
PRO A  26
ILE A  45
ILE A  51
GLY A  50
1.38A20.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2kqv NSP3
(SARSr-CoV)		5 / 12
ILE A  45
ILE A  51
GLY A  50
ILE A  27
PRO A  26
1.39A20.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2op9 REPLICASE
POLYPROTEIN 1AB
(PP1AB, ORF1AB)
3C-LIKE PROTEINASE
(3CL-PRO, 3CLP)
(SARSr-CoV)		5 / 13
ILE B 106
ASN B 133
ILE B 136
THR B 292
PHE B 294
1.64A24.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2op9 REPLICASE
POLYPROTEIN 1AB
(PP1AB, ORF1AB)
3C-LIKE PROTEINASE
(3CL-PRO, 3CLP)
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.63A24.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2op9 REPLICASE
POLYPROTEIN 1AB
(PP1AB, ORF1AB)
3C-LIKE PROTEINASE
(3CL-PRO, 3CLP)
(SARSr-CoV)		5 / 12
ILE B 136
GLY B 109
THR B 292
PHE B 294
ILE B 106
1.59A24.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2op9 REPLICASE
POLYPROTEIN 1AB
(PP1AB, ORF1AB)
3C-LIKE PROTEINASE
(3CL-PRO, 3CLP)
(SARSr-CoV)		5 / 12
ILE B 106
ILE B 136
GLY B 109
THR B 292
PHE B 294
1.59A24.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 13
THR D 195
ASN D  74
ILE B 314
ILE D  71
THR D 166
1.56A22.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		6 / 12
ARG A 257
VAL A 236
ALA A 255
LEU A 200
LEU A 248
LEU A 265
1.77A24.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2pwx 3C-LIKE PROTEINASE
(SARS-COV
BJ01)		5 / 13
PRO A 132
MET A 130
ILE A 249
THR A 111
PHE A 112
1.60A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2pwx 3C-LIKE PROTEINASE
(SARS-COV
BJ01)		5 / 12
PRO A 132
MET A 130
ILE A 249
THR A 111
PHE A 112
1.57A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2pwx 3C-LIKE PROTEINASE
(SARS-COV
BJ01)		5 / 12
ILE A 249
THR A 111
PHE A 112
PRO A 132
MET A 130
1.56A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		2q6g REPLICASE
POLYPROTEIN 1AB
(SARS-COV
BJ01)		5 / 11
GLU A 178
ASN A  84
HIS A 134
ILE A 106
LEU A  86
1.72A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2q6g REPLICASE
POLYPROTEIN 1AB
(SARS-COV
BJ01)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.51A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2q6g REPLICASE
POLYPROTEIN 1AB
(SARS-COV
BJ01)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.50A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2qc2 3C-LIKE PROTEINASE
(-)		5 / 13
ILE A 106
PRO A 108
ASN A 133
ILE A 136
THR A 292
1.60A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2qcy 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 13
PRO A 132
MET A 130
ILE A 249
THR A 111
PHE A 112
1.57A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2qcy 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
PRO A 132
MET A 130
ILE A 249
THR A 111
PHE A 112
1.55A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2qcy 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 249
THR A 111
PHE A 112
PRO A 132
MET A 130
1.54A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 12
THR D 112
SER D 117
VAL D  77
ALA D  81
LEU D 133
1.14A23.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		6 / 12
THR F 195
SER F 197
LEU F 297
LEU F 214
ILE F 252
LEU F 250
1.75A23.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 12
THR F 112
SER F 117
VAL F  77
ALA F  81
LEU F 133
1.21A23.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2vj1 MAIN PROTEINASE
(SARSr-CoV)		5 / 13
ILE B 106
PRO B 108
ASN B 133
ILE B 136
THR B 292
1.65A25.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2w2g NSP3
(SARSr-CoV)		5 / 12
ILE B 567
ILE B 573
GLY B 572
ILE B 549
PRO B 548
1.51A21.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		2w2g NSP3
(SARSr-CoV)		5 / 11
GLU A 618
LEU A 648
ARG A 628
ILE A 593
LEU A 617
1.68A20.07
None
None
SO4  A1653 (-2.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2w2g NSP3
(SARSr-CoV)		5 / 12
ILE B 549
PRO B 548
ILE B 567
ILE B 573
GLY B 572
1.51A21.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2w2g NSP3
(SARSr-CoV)		5 / 12
ILE A 549
PRO A 548
ILE A 567
ILE A 573
GLY A 572
1.52A21.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2w2g NSP3
(SARSr-CoV)		5 / 12
ILE A 390
ASP A 395
ILE A 394
THR A 486
PHE A 414
1.58A21.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		2w2g NSP3
(SARSr-CoV)		5 / 11
GLU B 618
LEU B 648
ARG B 628
ILE B 593
LEU B 617
1.71A20.07
None
None
SO4  B1653 (-2.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2w2g NSP3
(SARSr-CoV)		5 / 12
ILE A 567
ILE A 573
GLY A 572
ILE A 549
PRO A 548
1.52A21.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2wct NSP3
(SARSr-CoV)		5 / 12
ILE D 567
ILE D 573
GLY D 572
ILE D 549
PRO D 548
1.48A21.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2wct NSP3
(SARSr-CoV)		5 / 13
ILE C 459
PRO C 460
SER B 585
ILE C 449
ILE C 417
1.52A21.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2wct NSP3
(SARSr-CoV)		5 / 12
ILE C 567
ILE C 573
GLY C 572
ILE C 549
PRO C 548
1.49A21.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2wct NSP3
(SARSr-CoV)		5 / 13
ILE A 459
PRO A 460
SER D 585
ILE A 449
ILE A 417
1.54A21.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2wct NSP3
(SARSr-CoV)		5 / 13
ILE B 459
PRO B 460
SER C 585
ILE B 449
ILE B 417
1.52A21.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2wct NSP3
(SARSr-CoV)		5 / 12
ILE A 567
ILE A 573
GLY A 572
ILE A 549
PRO A 548
1.48A21.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2wct NSP3
(SARSr-CoV)		5 / 13
ILE D 459
PRO D 460
SER A 585
ILE D 449
ILE D 417
1.53A21.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2wct NSP3
(SARSr-CoV)		5 / 12
ILE D 549
PRO D 548
ILE D 567
ILE D 573
GLY D 572
1.48A21.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2wct NSP3
(SARSr-CoV)		5 / 12
ILE A 549
PRO A 548
ILE A 567
ILE A 573
GLY A 572
1.48A21.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2wct NSP3
(SARSr-CoV)		5 / 12
ILE B 567
ILE B 573
GLY B 572
ILE B 549
PRO B 548
1.49A21.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2wct NSP3
(SARSr-CoV)		5 / 12
ILE B 549
PRO B 548
ILE B 567
ILE B 573
GLY B 572
1.49A21.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2wct NSP3
(SARSr-CoV)		5 / 12
ILE C 549
PRO C 548
ILE C 567
ILE C 573
GLY C 572
1.48A21.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		2xyq PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		6 / 12
SER A 129
VAL A  67
ALA A 168
ILE A 157
LEU A 183
LEU A 180
1.69A21.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		2xyq PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		6 / 12
VAL A  67
ALA A 168
LEU A 161
ILE A 157
LEU A 183
LEU A 180
1.77A21.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		2xyr PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		6 / 12
VAL A  67
ALA A 168
LEU A 161
ILE A 157
LEU A 183
LEU A 180
1.80A21.01
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		2xyr PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		6 / 12
SER A 129
VAL A  67
ALA A 168
ILE A 157
LEU A 183
LEU A 180
1.71A21.01
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		2xyv PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		6 / 12
VAL A  67
ALA A 168
LEU A 161
ILE A 157
LEU A 183
LEU A 180
1.76A21.01
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		2xyv PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		6 / 12
SER A 129
VAL A  67
ALA A 168
ILE A 157
LEU A 183
LEU A 180
1.67A21.01
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		2z9g 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 10
THR A 201
ALA A 206
LEU A 205
GLN A 110
ILE A 249
1.40A22.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2z9j 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE B 106
ILE B 136
GLY B 109
THR B 292
PHE B 294
1.61A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		2z9j 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 11
GLU B 178
ASN B  84
HIS B 134
ILE B 106
LEU B  86
1.79A21.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		2z9l 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE B 106
ILE B 136
GLY B 109
THR B 292
PHE B 294
1.62A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3bgf F26G19 FAB
(Mus
musculus)		6 / 12
THR L 178
SER L 176
SER L 177
VAL H 165
LEU H 140
LEU H 143
1.66A20.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3bgf F26G19 FAB
SPIKE PROTEIN S1
(Mus
musculus;
SARSr-CoV)		6 / 13
ILE H  51
PRO H  52
THR H  31
ASN S 424
ILE S 489
THR H  93
1.64A19.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3bgf F26G19 FAB
SPIKE PROTEIN S1
(Mus
musculus;
SARSr-CoV)		6 / 13
ILE B  51
PRO B  52
THR B  31
ASN A 424
ILE A 489
THR B  93
1.65A19.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3bgf F26G19 FAB
(Mus
musculus)		6 / 12
THR C 178
SER C 176
SER C 177
VAL B 165
LEU B 140
LEU B 143
1.64A20.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0g ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
THR B 282
SER B 280
VAL B 293
LEU B 440
LEU B 439
1.26A18.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0g ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
SER A 257
ALA A 251
LEU A 281
LEU A 162
PRO A 263
LEU A 262
1.67A18.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0g ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
THR B 282
SER B 280
LEU B 278
LEU B 248
ILE B 256
1.42A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0g ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 10
THR B 282
ALA B 443
LEU B 444
ILE B 436
PRO B 284
ILE B 291
1.62A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0g ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
THR B 593
VAL B 581
LEU B 240
LEU B 539
PRO B 590
LEU B 591
1.74A18.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0g ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
THR A 282
SER A 280
LEU A 278
LEU A 248
ILE A 256
1.44A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3d0g ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
MET A 376
ASN A 330
ASP A 355
MET A 323
PHE A 315
1.60A19.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0g ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
SER B 257
ALA B 251
LEU B 281
LEU B 162
PRO B 263
LEU B 262
1.65A18.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0g ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 10
THR B 282
LEU B 444
GLN B 598
ILE B 436
PRO B 284
ILE B 291
1.73A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
THR B 282
SER B 280
LEU B 278
LEU B 248
ILE B 256
1.38A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
VAL B 573
LEU B 520
PRO B 583
LEU B 584
ILE B 446
1.45A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
VAL A 573
LEU A 520
PRO A 583
LEU A 584
ILE A 446
1.45A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 10
THR B 282
LEU B 444
GLN B 598
ILE B 436
PRO B 284
ILE B 291
1.75A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 10
THR B 282
ALA B 443
LEU B 444
ILE B 436
PRO B 284
ILE B 291
1.63A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
THR A 282
SER A 280
LEU A 278
LEU A 248
ILE A 256
1.38A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
THR B 282
SER B 280
VAL B 293
LEU B 440
LEU B 439
LEU B 444
1.44A18.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
SER B 257
ALA B 251
LEU B 281
LEU B 162
PRO B 263
LEU B 262
1.72A18.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
SER B 257
ALA B 251
LEU B 281
LEU B 162
PRO B 263
LEU B 262
1.68A18.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 10
THR B 282
LEU B 444
GLN B 598
ILE B 436
PRO B 284
ILE B 291
1.77A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
THR A 282
SER A 280
LEU A 278
LEU A 248
ILE A 256
1.41A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 13
ILE A 307
THR A 371
ILE A 358
MET A 360
THR A 334
1.65A19.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
MET A 376
ASN A 330
ASP A 355
MET A 323
PHE A 315
1.54A19.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
SER A 317
SER A 547
LEU A 320
LEU A 410
ILE A 407
LEU A 554
1.73A18.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 13
ILE B 307
THR B 371
ILE B 358
MET B 360
THR B 334
1.66A19.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
THR B 282
SER B 280
LEU B 278
LEU B 248
ILE B 256
1.40A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
VAL B 573
LEU B 520
PRO B 583
LEU B 584
ILE B 446
1.45A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 10
THR B 282
ALA B 443
LEU B 444
ILE B 436
PRO B 284
ILE B 291
1.62A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
SER A 257
ALA A 251
LEU A 281
LEU A 162
PRO A 263
LEU A 262
1.66A18.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
THR B 282
SER B 280
VAL B 293
LEU B 440
LEU B 439
LEU B 444
1.42A18.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3d62 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.57A23.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3d62 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.58A23.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3ea7 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE B 106
ILE B 136
GLY B 109
THR B 292
PHE B 294
1.64A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3f9f 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE B 136
GLY B 109
THR B 292
PHE B 294
ILE B 106
1.60A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3f9f 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE B 106
ILE B 136
GLY B 109
THR B 292
PHE B 294
1.61A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3f9f 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE B 106
ILE B 136
GLY B 109
THR B 292
PHE B 294
1.59A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3f9g 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.58A24.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3f9g 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.57A24.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		3f9g 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 11
GLU A 178
ASN A  84
HIS A 134
ILE A 106
LEU A  86
1.77A21.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3f9g 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.59A24.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3f9g 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 13
ILE B 106
ILE B 136
ILE B 200
THR B 292
PHE B 294
1.67A24.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3f9h 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE B 106
ILE B 136
GLY B 109
THR B 292
PHE B 294
1.57A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3f9h 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE B 106
ILE B 136
GLY B 109
THR B 292
PHE B 294
1.59A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3f9h 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE B 136
GLY B 109
THR B 292
PHE B 294
ILE B 106
1.58A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3fzd 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 13
ILE A 106
ASN A 133
ILE A 136
THR A 292
PHE A 294
1.63A24.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3fzd 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.56A24.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3fzd 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.57A24.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3i6g BETA-2-MICROGLOBULIN
(Homo
sapiens)		5 / 13
ILE B   7
PRO B   5
THR B  86
ASN B  83
ILE B  92
1.55A16.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3i6g BETA-2-MICROGLOBULIN
HLA, A-2
(Homo
sapiens)		5 / 12
SER A  92
ILE B  35
ASP B  34
THR A  10
PHE A  22
1.65A20.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3i6g BETA-2-MICROGLOBULIN
(Homo
sapiens)		5 / 13
ILE E   7
PRO E   5
THR E  86
ASN E  83
ILE E  92
1.56A16.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3i6g HLA, A-2
(Homo
sapiens)		5 / 12
GLY A 265
THR A 182
LEU A 215
GLN A 262
ILE A 213
1.49A20.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3i6g BETA-2-MICROGLOBULIN
HLA, A-2
(Homo
sapiens)		5 / 12
SER D  92
ILE E  35
ASP E  34
THR D  10
PHE D  22
1.55A20.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3i6g HLA, A-2
(Homo
sapiens)		5 / 12
GLY D 265
THR D 182
LEU D 215
GLN D 262
ILE D 213
1.49A20.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3i6k BETA-2-MICROGLOBULIN
(Homo
sapiens)		5 / 13
ILE B   7
PRO B   5
THR B  86
ASN B  83
ILE B  92
1.58A16.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3i6k HLA, A-2
(Homo
sapiens)		5 / 12
SER A 105
GLY E 265
THR E 182
LEU E 215
ILE E 213
1.58A20.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3i6k BETA-2-MICROGLOBULIN
(Homo
sapiens)		5 / 13
ILE F   7
PRO F   5
THR F  86
ASN F  83
ILE F  92
1.55A16.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3i6k HLA, A-2
(Homo
sapiens)		5 / 12
SER E 105
GLY A 265
THR A 182
LEU A 215
ILE A 213
1.56A20.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3i6l HLA, A-24
(Homo
sapiens)		5 / 12
GLY D 265
THR D 182
LEU D 215
GLN D 262
ILE D 213
1.43A21.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3i6l BETA-2-MICROGLOBULIN
(Homo
sapiens)		5 / 13
ILE E   7
PRO E   5
THR E  86
ASN E  83
ILE E  92
1.49A16.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		3iwm 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 11
LEU B 271
MET B 276
ASN B 277
ILE B 286
LEU D 205
1.73A21.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3m3s 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.51A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3m3s 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.50A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3m3t 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
PRO A 132
MET A 130
ILE A 249
THR A 111
PHE A 112
1.55A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3m3t 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 13
PRO A 132
MET A 130
ILE A 249
THR A 111
PHE A 112
1.57A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3m3t 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 249
THR A 111
PHE A 112
PRO A 132
MET A 130
1.54A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3m3v 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE B 106
ILE B 136
GLY B 109
THR B 292
PHE B 294
1.66A24.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		3mj5 REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		5 / 12
THR A 103
VAL A 126
ALA A 120
LEU A 119
LEU A 133
1.22A20.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		3mj5 REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		6 / 12
THR B 103
VAL B 126
ALA B 120
LEU B 119
LEU B 133
ILE B 152
1.66A20.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		3r24 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		6 / 12
SER A 129
VAL A  67
ALA A 168
ILE A 157
LEU A 183
LEU A 180
1.69A22.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		3r24 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		6 / 12
VAL A  67
ALA A 168
LEU A 161
ILE A 157
LEU A 183
LEU A 180
1.79A22.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3sci ACE2
(Homo
sapiens)		6 / 12
SER B 257
ALA B 251
LEU B 281
LEU B 162
PRO B 263
LEU B 262
1.71A19.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3sci ACE2
(Homo
sapiens)		6 / 10
THR B 282
ALA B 443
LEU B 444
ILE B 436
PRO B 284
ILE B 291
1.63A19.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3sci ACE2
(Homo
sapiens)		6 / 12
SER A 257
ALA A 251
LEU A 281
LEU A 162
PRO A 263
LEU A 262
1.61A19.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3sci ACE2
(Homo
sapiens)		6 / 12
ALA A 251
LEU A 248
LEU A 281
LEU A 162
PRO A 263
LEU A 262
1.74A19.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3sci ACE2
(Homo
sapiens)		5 / 12
THR B 282
SER B 280
VAL B 293
LEU B 440
LEU B 439
1.25A19.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3sci ACE2
(Homo
sapiens)		5 / 10
VAL A 573
LEU A 520
PRO A 583
LEU A 584
ILE A 446
1.47A19.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3scj ACE2
(Homo
sapiens)		6 / 10
THR B 282
ALA B 443
LEU B 444
ILE B 436
PRO B 284
ILE B 291
1.65A19.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		3scj ACE2
(Homo
sapiens)		5 / 11
ASN B 397
LEU B 570
MET B 557
ASN B 556
ILE B 407
1.76A16.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3scj ACE2
(Homo
sapiens)		6 / 12
SER A 257
ALA A 251
LEU A 281
LEU A 162
PRO A 263
LEU A 262
1.66A19.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		3scj ACE2
(Homo
sapiens)		5 / 11
GLU B 181
MET B 474
HIS B 493
ARG B 169
SER B 170
1.52A16.12
None
None
None
CL  B 902 (-3.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3scj ACE2
(Homo
sapiens)		5 / 10
VAL A 573
LEU A 520
PRO A 583
LEU A 584
ILE A 446
1.43A19.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		3scj ACE2
(Homo
sapiens)		5 / 11
GLU A 181
MET A 474
HIS A 493
ARG A 169
SER A 170
1.52A16.12
None
None
None
CL  A 902 (-4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
THR B 282
SER B 280
LEU B 278
LEU B 248
ILE B 256
1.46A19.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
VAL B 573
LEU B 520
PRO B 583
LEU B 584
ILE B 446
1.47A19.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
SER A 317
SER A 547
LEU A 320
LEU A 410
ILE A 407
LEU A 554
1.73A18.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
SER B 317
SER B 547
LEU B 320
LEU B 410
ILE B 407
LEU B 554
1.77A18.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
THR A 282
SER A 280
LEU A 278
LEU A 248
ILE A 256
1.45A19.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
THR B 371
VAL B 318
ALA B 412
ILE B 407
ILE B 446
1.44A19.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 10
THR B 282
ALA B 443
LEU B 444
ILE B 436
PRO B 284
ILE B 291
1.72A19.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
SER A 257
ALA A 251
LEU A 281
LEU A 162
PRO A 263
LEU A 262
1.66A18.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
SER A 257
ALA A 251
LEU A 281
LEU A 162
PRO A 263
LEU A 262
1.61A18.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
THR A 282
SER A 280
LEU A 278
LEU A 248
ILE A 256
1.45A19.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
THR B 282
SER B 280
LEU B 278
LEU B 248
ILE B 256
1.48A19.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
VAL B 573
LEU B 520
PRO B 583
LEU B 584
ILE B 446
1.46A19.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 11
ASN B 121
MET B  62
ASN B  61
SER B  70
LEU B 120
1.74A15.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 10
THR B 282
ALA B 443
LEU B 444
ILE B 436
PRO B 284
ILE B 291
1.69A19.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
ALA A 251
LEU A 248
LEU A 281
LEU A 162
PRO A 263
LEU A 262
1.79A18.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3snd 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE B 106
ILE B 136
GLY B 109
THR B 292
PHE B 294
1.60A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3snd 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE B 136
GLY B 109
THR B 292
PHE B 294
ILE B 106
1.59A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3snd 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.65A24.32
None
None
MRD  A 307 (-3.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3to2 MHC CLASS I ANTIGEN
(Homo
sapiens)		5 / 12
GLY A 265
THR A 182
LEU A 215
GLN A 262
ILE A 213
1.48A20.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3to2 BETA-2-MICROGLOBULIN
(Homo
sapiens)		5 / 13
ILE B   7
PRO B   5
THR B  86
ASN B  83
ILE B  92
1.56A16.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3v3m 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.51A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3v3m 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.51A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3vb5 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE B 136
GLY B 109
THR B 292
PHE B 294
ILE B 106
1.59A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3vb5 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.66A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		3vb5 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ILE B 106
ILE B 136
GLY B 109
THR B 292
PHE B 294
1.60A24.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		4mm3 PAPAIN-LIKE
PROTEINASE
(SARSr-CoV)		5 / 12
THR B 103
VAL B 126
ALA B 120
LEU B 119
LEU B 133
1.22A20.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		4ovz PAPAIN-LIKE
PROTEINASE
(SARS-COV
Urbani)		6 / 12
THR B 103
VAL B 126
ALA B 120
LEU B 119
LEU B 133
ILE B 152
1.65A20.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		4ovz PAPAIN-LIKE
PROTEINASE
(SARS-COV
Urbani)		5 / 12
THR A 103
VAL A 126
ALA A 120
LEU A 119
LEU A 133
1.23A20.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		4ow0 PAPAIN-LIKE PROTEASE
(SARS-COV
Urbani)		5 / 12
THR A 103
VAL A 126
ALA A 120
LEU A 119
LEU A 133
1.18A20.94
None
DMS  A 905 ( 4.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		4ow0 PAPAIN-LIKE PROTEASE
(SARS-COV
Urbani)		5 / 12
THR B 103
VAL B 126
ALA B 120
LEU B 119
LEU B 133
1.15A20.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		4tww 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 11
LEU B 271
MET B 276
ASN B 277
ILE B 286
LEU B 205
1.50A21.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
GLN B 246
MET B  62
GLY B 189
THR B 193
PHE B  60
1.34A21.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
SER D  12
ILE D  14
GLY D  17
LEU D  27
PRO D  24
1.57A21.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 11
ASN B 410
LEU B 411
SER B 112
ILE B 275
LEU B 406
1.54A18.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
GLN D 246
MET D  62
GLY D 189
THR D 193
PHE D  60
1.59A21.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
GLY B 189
THR B 193
PHE B  60
GLN B 246
MET B  62
1.36A21.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
GLN B 246
MET B  62
GLY B 189
THR B 193
PHE B  60
1.36A21.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5c8t GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
GLN B 246
MET B  62
GLY B 189
THR B 193
PHE B  60
1.33A21.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5c8t GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
GLN B 246
MET B  62
GLY B 189
THR B 193
PHE B  60
1.31A21.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5c8t GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
GLN D 246
MET D  62
GLY D 189
THR D 193
PHE D  60
1.63A21.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5c8t GUANINE-N7
METHYLTRANSFERASE
NSP10
(SARSr-CoV)		5 / 13
PRO B  24
SER B  12
ASN A   3
ILE B  31
ILE B  14
1.61A21.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		5c8t GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 11
ASN B 410
LEU B 411
SER B 112
ILE B 275
LEU B 406
1.47A18.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5c8t GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
GLY B 189
THR B 193
PHE B  60
GLN B 246
MET B  62
1.32A21.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5c8u GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
GLN B 246
MET B  62
GLY B 189
THR B 193
PHE B  60
1.35A21.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5c8u GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
GLY B 189
THR B 193
PHE B  60
GLN B 246
MET B  62
1.36A21.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5c8u GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
GLN D 246
MET D  62
GLY D 189
THR D 193
PHE D  60
1.49A21.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		5c8u GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 11
ASN B 410
LEU B 411
SER B 112
ILE B 275
LEU B 406
1.41A18.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5c8u GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
GLN B 246
MET B  62
GLY B 189
THR B 193
PHE B  60
1.37A21.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5c8u GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
GLY D 189
THR D 193
PHE D  60
GLN D 246
MET D  62
1.48A21.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5c8u GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
GLN D 246
MET D  62
GLY D 189
THR D 193
PHE D  60
1.45A21.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		5c8u GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 11
GLU D 295
LEU B 366
HIS B 330
ARG D 304
SER D 307
1.73A18.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5c8u GUANINE-N7
METHYLTRANSFERASE
NSP10
(SARSr-CoV)		5 / 13
PRO B  24
SER B  12
ASN A   3
ILE B  31
ILE B  14
1.45A21.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5e6j UBIQUITIN
(synthetic
construct)		5 / 13
GLN E  41
THR E   7
ILE E  23
THR E  66
PHE E   4
1.66A12.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		5e6j REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
THR A 103
VAL A 126
ALA A 120
LEU A 119
LEU A 133
1.20A21.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		5e6j REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
THR D 103
VAL D 126
ALA D 120
LEU D 119
LEU D 133
1.22A21.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5e6j UBIQUITIN
(synthetic
construct)		5 / 13
GLN B  41
THR B   7
ILE B  23
THR B  66
PHE B   4
1.62A12.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		5 / 10
VAL C  91
ALA C 119
LEU C 157
ILE C 166
ILE C 164
1.19A20.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		5 / 12
GLN D 246
MET D  62
GLY D 189
THR D 193
PHE D  60
1.60A21.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		5 / 12
GLN C 246
MET C  62
GLY C 189
THR C 193
PHE C  60
1.65A21.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5tl6 UBIQUITIN-LIKE
PROTEIN ISG15
(Homo
sapiens)		5 / 12
THR C 125
PHE C 149
LEU C  82
GLN C 102
ILE C  84
1.59A13.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		5tl6 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
THR B 103
VAL B 126
ALA B 120
LEU B 119
LEU B 133
1.14A20.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		5tl6 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		6 / 12
THR D 103
VAL D 126
ALA D 120
LEU D 119
LEU D 133
ILE D 152
1.75A20.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		5tl6 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		6 / 12
THR B 103
VAL B 126
ALA B 120
LEU B 119
LEU B 173
LEU B 114
1.77A20.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5tl7 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 13
GLN B  31
ILE B   6
ILE B  45
THR B  55
PHE B   9
1.60A22.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		5wrg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR C 760
SER C 712
ALA C 753
PRO C 845
LEU C 846
1.42A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		5wrg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR B 760
SER B 712
ALA B 753
PRO B 845
LEU B 846
1.42A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		5wrg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR A 760
SER A 712
ALA A 753
PRO A 845
LEU A 846
1.42A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x4r S PROTEIN
(MERS-CoV)		5 / 12
ILE A  57
ILE A 333
ILE A  48
GLY A  55
PHE A 254
1.61A22.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
GLN C1095
ILE C1097
SER C1093
THR C1059
PHE C1079
1.65A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 13
GLN C 786
PRO C1035
THR C 863
ILE C 916
MET C1032
1.64A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
VAL C 945
LEU C 959
LEU C 986
ILE C 724
LEU C 735
1.22A13.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
SER A  49
ILE C 570
GLY C 552
THR C 559
PHE C 558
1.52A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
GLY C 862
THR C 865
LEU C 788
GLN C1036
ILE C 787
1.54A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
GLN A1095
ILE A1097
SER A1093
THR A1059
PHE A1079
1.66A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
SER B  49
ILE A 570
GLY A 552
THR A 559
PHE A 558
1.52A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 13
GLN C1095
ILE C1097
SER C1093
THR C1059
PHE C1079
1.65A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
ILE C 694
PRO A 879
THR A 865
ILE C 687
THR A 869
1.55A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		6 / 12
THR B 980
ARG B 982
VAL B 958
ALA B 954
LEU B 963
ILE B 975
1.77A13.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
THR B 588
SER B 591
SER B 592
VAL B 675
ILE B 584
1.13A14.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
GLY A 862
THR A 865
LEU A 788
GLN A1036
ILE A 787
1.54A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
VAL A 945
LEU A 959
LEU A 986
ILE A 724
LEU A 735
1.22A13.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
ILE A 694
PRO B 879
THR B 865
ILE A 687
THR B 869
1.55A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
SER B  49
ILE A 570
GLY A 552
THR A 559
PHE A 558
1.55A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 13
GLN A 786
PRO A1035
THR A 863
ILE A 916
MET A1032
1.64A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 13
GLN B 786
PRO B1035
THR B 863
ILE B 916
MET B1032
1.64A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
SER A  49
ILE C 570
GLY C 552
THR C 559
PHE C 558
1.52A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
SER C  49
ILE B 570
GLY B 552
THR B 559
PHE B 558
1.55A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
THR C 588
SER C 591
SER C 592
VAL C 675
ILE C 584
1.13A14.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
SER C  49
ILE B 570
GLY B 552
THR B 559
PHE B 558
1.52A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
SER A  49
ILE C 570
GLY C 552
THR C 559
PHE C 558
1.55A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
SER B  49
ILE A 570
GLY A 552
THR A 559
PHE A 558
1.52A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
GLY B 862
THR B 865
LEU B 788
GLN B1036
ILE B 787
1.54A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 13
GLN A1095
ILE A1097
SER A1093
THR A1059
PHE A1079
1.66A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		6 / 12
THR A 980
ARG A 982
VAL A 958
ALA A 954
LEU A 963
ILE A 975
1.77A13.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
VAL B 945
LEU B 959
LEU B 986
ILE B 724
LEU B 735
1.22A13.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
GLN B1095
ILE B1097
SER B1093
THR B1059
PHE B1079
1.66A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		6 / 12
THR C 980
ARG C 982
VAL C 958
ALA C 954
LEU C 963
ILE C 975
1.77A13.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
THR A 588
SER A 591
SER A 592
VAL A 675
ILE A 584
1.13A14.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 13
GLN B1095
ILE B1097
SER B1093
THR B1059
PHE B1079
1.66A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
SER C  49
ILE B 570
GLY B 552
THR B 559
PHE B 558
1.52A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x59 S PROTEIN
(MERS-CoV)		5 / 12
ILE A  57
ILE A 333
ILE A  48
GLY A  55
PHE A 254
1.61A14.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x59 S PROTEIN
(MERS-CoV)		5 / 12
ILE C  57
ILE C 333
ILE C  48
GLY C  55
PHE C 254
1.61A14.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 10
THR C 869
LEU C 876
GLN B1088
ILE B 696
PRO B 697
1.36A14.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		6 / 12
SER B 957
VAL B 945
LEU B 959
LEU B 986
ILE B 724
LEU B 735
1.64A13.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
ILE B 694
PRO C 879
THR C 865
ILE B 687
THR C 869
1.55A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		6 / 12
SER C 957
VAL C 945
LEU C 959
LEU C 986
ILE C 724
LEU C 735
1.64A13.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
ALA B 732
LEU B 736
LEU B 978
ILE B 975
ILE B 979
1.21A13.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
THR A 588
SER A 591
SER A 592
VAL A 675
ILE A 584
1.31A14.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 13
GLN B 786
PRO B1035
THR B 863
ILE B 916
MET B1032
1.62A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 13
GLN C 786
PRO C1035
THR C 863
ILE C 916
MET C1032
1.62A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
GLN A1095
ILE A1097
SER A1093
THR A1059
PHE A1079
1.65A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 13
GLN A1095
ILE A1097
SER A1093
THR A1059
PHE A1079
1.65A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
ALA C 732
LEU C 736
LEU C 978
ILE C 975
ILE C 979
1.21A13.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		5x5c S PROTEIN
(MERS-CoV)		6 / 12
THR B 412
SER B 416
LEU B 411
LEU B 441
LEU B 481
ILE B 480
1.50A14.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x5c S PROTEIN
(MERS-CoV)		5 / 12
ILE B  57
ILE B 333
ILE B  48
GLY B  55
PHE B 254
1.61A14.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x5c S PROTEIN
(MERS-CoV)		5 / 12
ILE C  57
ILE C 333
ILE C  48
GLY C  55
PHE C 254
1.61A14.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5x5f S PROTEIN
(MERS-CoV)		5 / 12
ILE C  57
ILE C 333
ILE C  48
GLY C  55
PHE C 254
1.61A14.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
LEU C 944
LEU C 840
LEU C 994
GLN C 992
LEU C 986
1.32A14.81
LEU  C 944 ( 0.6A)
LEU  C 840 ( 0.6A)
LEU  C 994 ( 0.6A)
GLN  C 992 ( 0.6A)
LEU  C 986 ( 0.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR A 760
SER A 712
ALA A 753
PRO A 845
LEU A 846
1.40A14.72
THR  A 760 ( 0.8A)
SER  A 712 ( 0.0A)
ALA  A 753 ( 0.0A)
PRO  A 845 ( 1.1A)
LEU  A 846 ( 0.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR B 760
SER B 712
ALA B 753
PRO B 845
LEU B 846
1.39A14.72
THR  B 760 ( 0.8A)
SER  B 712 ( 0.0A)
ALA  B 753 ( 0.0A)
PRO  B 845 ( 1.1A)
LEU  B 846 ( 0.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
LEU A 944
LEU A 840
LEU A 994
GLN A 992
LEU A 986
1.33A14.81
LEU  A 944 ( 0.6A)
LEU  A 840 ( 0.6A)
LEU  A 994 ( 0.6A)
GLN  A 992 ( 0.6A)
LEU  A 986 ( 0.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR C 760
SER C 712
ALA C 753
PRO C 845
LEU C 846
1.39A14.72
THR  C 760 ( 0.8A)
SER  C 712 ( 0.0A)
ALA  C 753 ( 0.0A)
PRO  C 845 ( 1.1A)
LEU  C 846 ( 0.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		5y3e REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		6 / 12
THR A 103
VAL A 126
ALA A 120
LEU A 119
LEU A 133
ILE A 152
1.60A20.66
None
None
NA  A 403 ( 3.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		5y3e REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		6 / 12
THR A 103
VAL A 126
ALA A 120
LEU A 119
LEU A 133
ILE A 152
1.77A20.51
None
None
NA  A 403 ( 3.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		5y3q REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		6 / 12
THR A 103
VAL A 126
ALA A 120
LEU A 119
LEU A 133
ILE A 152
1.64A20.66
None
None
NA  A 404 ( 3.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR B 760
SER B 712
ALA B 753
PRO B 845
LEU B 846
1.27A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
THR A 706
ALA A 912
ILE A 787
ILE A 800
LEU A 803
LEU A 920
1.69A14.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR A 760
SER A 712
ALA A 753
PRO A 845
LEU A 846
1.24A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR A 760
SER A 712
ALA A 753
PRO A 845
LEU A 846
1.26A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
SER A 712
ALA A 753
PRO A 845
LEU A 846
ILE B 652
1.47A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR B 588
SER B 591
SER B 592
VAL B 675
ILE B 584
1.29A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR B 760
SER B 712
ALA B 753
PRO B 845
LEU B 846
1.25A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR C 588
SER C 591
SER C 592
VAL C 675
ILE C 584
1.29A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
VAL B 860
LEU B1045
ILE B 787
ILE B 800
LEU B 920
LEU B 803
1.75A14.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR C 760
SER C 712
ALA C 753
PRO C 845
LEU C 846
1.26A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
SER C 712
ALA C 753
PRO C 845
LEU C 846
ILE A 652
1.47A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
VAL C 860
LEU C1045
ILE C 787
ILE C 800
LEU C 920
LEU C 803
1.74A14.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
VAL A 860
LEU A1045
ILE A 787
ILE A 800
LEU A 920
LEU A 803
1.73A14.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR C 760
SER C 712
ALA C 753
PRO C 845
LEU C 846
1.28A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR A 588
SER A 591
SER A 592
VAL A 675
ILE A 584
1.28A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
SER B 712
ALA B 753
PRO B 845
LEU B 846
ILE C 652
1.48A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
THR B 706
ALA B 912
ILE B 787
ILE B 800
LEU B 803
LEU B 920
1.70A14.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
THR C 706
ALA C 912
ILE C 787
ILE C 800
LEU C 803
LEU C 920
1.69A14.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR C 760
SER C 712
ALA C 753
PRO C 845
LEU C 846
1.27A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ILE A 520
ILE A 570
ILE A 573
GLY A 536
THR A 535
1.61A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
VAL B 945
LEU B 959
LEU B 986
ILE B 724
LEU B 735
1.11A14.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
THR A 706
ALA A 912
ILE A 787
ILE A 800
LEU A 803
LEU A 920
1.60A14.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
ASN B 409
ASN A 158
SER A 105
ILE A 226
LEU B 448
1.75A9.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
SER A 712
ALA A 753
PRO A 845
LEU A 846
ILE B 652
1.44A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ILE B 520
ILE B 570
ILE B 573
GLY B 536
THR B 535
1.62A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
THR C 706
ALA C 912
ILE C 787
ILE C 800
LEU C 803
LEU C 920
1.68A14.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR C 760
SER C 712
ALA C 753
PRO C 845
LEU C 846
1.29A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR B 588
SER B 591
SER B 592
VAL B 675
ILE B 584
1.26A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR C 588
SER C 591
SER C 592
VAL C 675
ILE C 584
1.23A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
THR B 706
ALA B 912
ILE B 787
ILE B 800
LEU B 803
LEU B 920
1.68A14.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
VAL B 860
LEU B1045
ILE B 787
ILE B 800
LEU B 920
LEU B 803
1.76A14.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
SER B 712
ALA B 753
PRO B 845
LEU B 846
ILE C 652
1.40A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR B 760
SER B 712
ALA B 753
PRO B 845
LEU B 846
1.32A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR A 588
SER A 591
SER A 592
VAL A 675
ILE A 584
1.32A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR A 760
SER A 712
ALA A 753
PRO A 845
LEU A 846
1.29A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acg ACE2
(Homo
sapiens)		6 / 12
THR D 371
VAL D 318
ALA D 412
LEU D 370
LEU D 554
ILE D 407
1.67A19.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ILE A 520
ILE A 570
ILE A 573
GLY A 536
THR A 535
1.63A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 13
ILE A1115
THR A1098
ILE A1112
THR A1087
PHE A1085
1.64A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ILE C 674
MET C 679
THR C 678
ILE C 652
PRO C 651
1.58A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
SER B1083
ASN B1080
ILE B1112
ILE B1115
THR B1102
1.59A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
THR C 588
SER C 591
SER C 592
VAL C 675
LEU C 597
ILE C 584
1.57A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
SER B 956
VAL B 945
LEU B 959
LEU B 986
ILE B 724
LEU B 735
1.68A14.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 13
ILE A 652
PRO A 651
ILE A 674
MET A 679
THR A 678
1.57A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ILE C 520
ILE C 570
ILE C 573
GLY C 536
THR C 535
1.66A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		6acg ACE2
(Homo
sapiens)		5 / 11
GLU D 527
HIS D 417
SER D 409
ILE D 407
LEU D 584
1.69A16.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 13
ILE C 652
PRO C 651
ILE C 674
MET C 679
THR C 678
1.58A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
SER A 712
ALA A 753
PRO A 845
LEU A 846
ILE B 652
1.38A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR C 988
VAL A 990
GLN A 992
ILE B 995
ILE B 752
1.43A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR C 160
VAL C 123
LEU C 224
LEU C 194
ILE C 115
1.26A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR B 760
SER B 712
ALA B 753
PRO B 845
LEU B 846
1.32A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ILE C 652
PRO C 651
ILE C 674
MET C 679
THR C 678
1.58A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6acg ACE2
(Homo
sapiens)		5 / 13
ILE D 307
THR D 371
ILE D 358
MET D 360
THR D 334
1.60A20.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR A 760
SER A 712
ALA A 753
PRO A 845
LEU A 846
1.28A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR A 760
SER A 712
ALA A 753
PRO A 845
LEU A 846
1.27A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR B 760
SER B 712
ALA B 753
PRO B 845
LEU B 846
1.29A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		6acg ACE2
(Homo
sapiens)		5 / 11
GLU D 181
MET D 474
HIS D 493
ARG D 169
SER D 170
1.42A16.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 13
ILE A 702
SER A 914
ASN A 910
ILE A 913
THR A 705
1.65A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
SER C 985
VAL C 718
ILE C 724
LEU C 978
ILE C 962
1.48A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 13
SER B1083
ASN B1080
ILE B1112
ILE B1115
THR B1102
1.61A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6acg ACE2
(Homo
sapiens)		5 / 12
ILE D 307
THR D 371
ILE D 358
MET D 360
THR D 334
1.60A20.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 13
ILE C 652
PRO C 651
ILE C 674
MET C 679
THR C 678
1.57A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
SER B 712
ALA B 753
PRO B 845
LEU B 846
ILE C 652
1.44A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
VAL A 860
LEU A1045
ILE A 787
ILE A 800
LEU A 920
LEU A 803
1.80A14.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
VAL A 945
LEU A 959
LEU A 986
ILE A 724
LEU A 735
1.23A14.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR A 760
SER A 712
ALA A 753
PRO A 845
LEU A 846
1.25A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ILE C 652
PRO C 651
ILE C 674
MET C 679
THR C 678
1.57A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acj ACE2
(Homo
sapiens)		5 / 10
VAL D 573
LEU D 520
PRO D 583
LEU D 584
ILE D 446
1.43A19.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ILE C 674
MET C 679
THR C 678
ILE C 652
PRO C 651
1.56A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
THR C 706
ALA C 912
ILE C 787
ILE C 800
LEU C 803
LEU C 920
1.51A14.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ASP B  24
ILE B 244
GLY B 246
THR B 236
PHE B 138
1.66A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR B 588
SER B 591
SER B 592
VAL B 675
ILE B 584
1.24A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR C 760
SER C 712
ALA C 753
PRO C 845
LEU C 846
1.23A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR B 760
SER B 712
ALA B 753
PRO B 845
LEU B 846
1.25A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR C 760
SER C 712
ALA C 753
PRO C 845
LEU C 846
1.21A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR B 760
SER B 712
ALA B 753
PRO B 845
LEU B 846
1.23A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR A 760
SER A 712
ALA A 753
PRO A 845
LEU A 846
1.23A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR B 760
SER B 712
ALA B 753
PRO B 845
LEU B 846
1.26A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR B 760
SER B 712
ALA B 753
PRO B 845
LEU B 846
1.32A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
VAL A 897
ILE A 696
PRO A 697
LEU C 876
ILE C 878
1.40A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR C 760
SER C 712
ALA C 753
PRO C 845
LEU C 846
1.21A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6ack ACE2
(Homo
sapiens)		6 / 12
SER D 257
ALA D 251
LEU D 281
LEU D 162
PRO D 263
LEU D 262
1.62A19.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 13
ILE C 652
PRO C 651
ILE C 674
MET C 679
THR C 678
1.64A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
THR C 588
SER C 591
SER C 592
VAL C 675
LEU C 597
ILE C 584
1.66A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR C 760
SER C 712
ALA C 753
PRO C 845
LEU C 846
1.23A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR A 760
SER A 712
ALA A 753
PRO A 845
LEU A 846
1.27A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
THR C 706
ALA C 912
ILE C 787
ILE C 800
LEU C 803
LEU C 920
1.73A14.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR A 760
SER A 712
ALA A 753
PRO A 845
LEU A 846
1.29A14.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
SER B 956
VAL B 945
LEU B 959
LEU B 986
ILE B 724
LEU B 735
1.58A14.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ILE A 228
ILE A  87
GLY A  86
PHE A  59
LEU A 222
1.46A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER B  49
ILE A 570
GLY A 552
THR A 559
PHE A 558
1.64A15.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
VAL C 860
LEU C1045
ILE C 787
ILE C 800
LEU C 920
LEU C 803
1.64A14.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER A  49
ILE C 570
GLY C 552
THR C 559
PHE C 558
1.60A15.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
SER A 690
ALA B 864
LEU B 876
GLN B 877
ILE B 878
PRO B 879
1.79A14.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
VAL B 860
LEU B1045
ILE B 787
ILE B 800
LEU B 920
LEU B 803
1.64A14.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
VAL A 860
LEU A1045
ILE A 787
ILE A 800
LEU A 920
LEU A 803
1.64A14.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 13
ILE C 652
PRO C 651
ILE C 674
MET C 679
THR C 678
1.65A15.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
SER C 690
ALA A 864
LEU A 876
GLN A 877
ILE A 878
PRO A 879
1.77A14.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER B  49
ILE A 570
GLY A 552
THR A 559
PHE A 558
1.61A15.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 13
ILE B 652
PRO B 651
ILE B 674
MET B 679
THR B 678
1.65A15.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
SER B 690
ALA C 864
LEU C 876
GLN C 877
ILE C 878
PRO C 879
1.74A14.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
VAL A 990
GLN A 992
ILE C 995
LEU C 994
ILE C 752
1.48A14.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER C  49
ILE B 570
GLY B 552
THR B 559
PHE B 558
1.61A15.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 13
ILE A 652
PRO A 651
ILE A 674
MET A 679
THR A 678
1.65A15.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER B  49
ILE A 570
GLY A 552
THR A 559
PHE A 558
1.35A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER B  49
ILE A 570
GLY A 552
THR A 559
PHE A 558
1.36A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 13
ILE C 455
THR A 106
ASN A 227
ILE A 226
PHE A 157
1.51A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
ILE C 637
THR C 604
GLY C 634
THR C 631
PHE C 629
1.58A14.94
None
NAG  C1311 ( 4.3A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 13
ILE C 455
THR A 106
SER A 105
ASN A 227
PHE A 157
1.67A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
PRO B 879
MET B 882
THR A1059
ILE A1115
GLY A1113
1.55A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER B  49
ILE A 570
GLY A 552
THR A 559
PHE A 558
1.35A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
VAL C 860
LEU C1045
ILE C 787
ILE C 800
LEU C 920
LEU C 803
1.60A14.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
ILE C 234
PRO C 136
ILE C  81
GLY C  77
THR C  71
1.59A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 13
ILE A  72
THR A  92
ASN A 178
THR A  31
PHE A  69
1.62A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
ILE B 724
SER B 717
ASN B 746
ASP B 719
GLY B 839
1.63A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
VAL B 860
LEU B1045
ILE B 787
ILE B 800
LEU B 920
LEU B 803
1.58A14.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER A 985
ILE B 979
GLY B 739
LEU B 986
GLN B 987
1.50A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
VAL A 860
LEU A1045
ILE A 787
ILE A 800
LEU A 920
LEU A 803
1.58A14.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 13
ILE A 878
MET A 882
THR C1059
ASN C1056
ILE C 687
1.48A14.94
None
None
None
NAG  C1319 (-2.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
LEU A 944
LEU A 840
LEU A 994
GLN A 992
LEU A 986
1.32A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER C  49
ILE B 570
GLY B 552
THR B 559
PHE B 558
1.25A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER C  49
ILE B 570
GLY B 552
THR B 559
PHE B 558
1.25A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
THR C 760
SER C 712
ALA C 753
PRO C 845
LEU C 846
1.45A14.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER C  49
ILE B 570
GLY B 552
THR B 559
PHE C 837
1.66A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
VAL B 860
LEU B1045
ILE B 787
ILE B 800
LEU B 920
LEU B 803
1.64A14.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
VAL A 860
LEU A1045
ILE A 787
ILE A 800
LEU A 920
LEU A 803
1.61A14.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
THR A 706
ALA A 912
ILE A 787
ILE A 800
LEU A 803
LEU A 920
1.77A14.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER B  49
ILE A 570
GLY A 552
THR A 559
PHE A 558
1.58A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER A  49
ILE C 570
GLY C 552
THR C 559
PHE C 558
1.39A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
SER B 690
ALA C 864
LEU C 876
GLN C 877
ILE C 878
PRO C 879
1.77A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER A  49
ILE C 570
GLY C 552
THR C 559
PHE C 558
1.39A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
THR B 706
ALA B 912
ILE B 787
ILE B 800
LEU B 803
LEU B 920
1.73A14.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER B  49
ILE A 570
GLY A 552
THR A 559
PHE A 558
1.57A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER A  49
ILE C 570
GLY C 552
THR C 559
PHE C 558
1.41A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
ILE C 584
ILE C 637
GLY C 638
LEU C 286
PRO C 282
1.47A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER C  49
ILE B 570
GLY B 552
THR B 559
PHE B 558
1.24A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crz SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
ILE B 724
SER B 717
ASN B 746
ASP B 719
GLY B 839
1.64A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6crz SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
VAL B 860
LEU B1045
ILE B 787
ILE B 800
LEU B 920
LEU B 803
1.70A14.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crz SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER A 985
ILE B 979
GLY B 739
LEU B 986
GLN B 987
1.46A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		6crz SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 11
GLU B 131
ASN B 109
LEU B 132
ASN B 135
ILE B 117
1.46A9.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6crz SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
THR C 760
SER C 712
ALA C 753
PRO C 845
LEU C 846
1.33A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crz SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 13
ILE C 652
PRO C 651
ILE C 674
MET C 679
THR C 678
1.63A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crz SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
GLN B 630
ILE C 826
ASN B 602
ILE C 832
GLY C 824
1.58A14.94
NAG  B1309 ( 4.7A)
None
NAG  B1309 (-1.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crz SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
GLN A 895
THR C1102
GLY C1075
THR C1087
PHE C1085
1.39A14.94
None
None
None
None
NAG  C1321 (-3.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crz SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 13
ILE C 455
THR A 106
ASN A 227
ILE A 226
PHE A 157
1.48A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6crz SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 13
ILE B 694
PRO C 879
THR C 865
ILE B 687
THR C 869
1.63A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6crz SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
VAL A 860
LEU A1045
ILE A 787
ILE A 800
LEU A 920
LEU A 803
1.69A14.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6crz SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
SER C 712
ALA C 753
PRO C 845
LEU C 846
ILE B 652
1.47A14.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6crz SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
THR C 760
SER C 712
ALA C 753
PRO C 845
LEU C 846
1.28A14.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6crz SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
VAL C 860
LEU C1045
ILE C 787
ILE C 800
LEU C 920
LEU C 803
1.65A14.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 11
GLU B 131
ASN B 109
LEU B 132
ASN B 135
ILE B 117
1.46A9.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
THR C 760
SER C 712
ALA C 753
PRO C 845
LEU C 846
1.28A14.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 13
ILE C 455
THR A 106
ASN A 227
ILE A 226
PHE A 157
1.48A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 13
ILE B 694
PRO C 879
THR C 865
ILE B 687
THR C 869
1.63A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
GLN B 630
ILE C 826
ASN B 602
ILE C 832
GLY C 824
1.58A14.94
NAG  B1309 ( 4.7A)
None
NAG  B1309 (-1.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
ILE B 724
SER B 717
ASN B 746
ASP B 719
GLY B 839
1.64A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
VAL B 860
LEU B1045
ILE B 787
ILE B 800
LEU B 920
LEU B 803
1.70A14.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER A 985
ILE B 979
GLY B 739
LEU B 986
GLN B 987
1.46A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 13
ILE C 652
PRO C 651
ILE C 674
MET C 679
THR C 678
1.63A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
VAL C 860
LEU C1045
ILE C 787
ILE C 800
LEU C 920
LEU C 803
1.65A14.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
GLN A 895
THR C1102
GLY C1075
THR C1087
PHE C1085
1.39A14.94
None
None
None
None
NAG  C1321 (-3.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
VAL A 860
LEU A1045
ILE A 787
ILE A 800
LEU A 920
LEU A 803
1.69A14.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
SER C 712
ALA C 753
PRO C 845
LEU C 846
ILE B 652
1.47A14.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER B  49
ILE A 570
GLY A 552
THR A 559
PHE B 837
1.55A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER A  49
ILE C 570
GLY C 552
THR C 559
PHE C 558
1.57A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER A  49
ILE C 570
GLY C 552
THR C 559
PHE C 558
1.55A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
THR A 760
SER A 712
ALA A 754
PRO A 845
LEU A 846
1.33A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER B 582
GLY B 634
PHE B 629
LEU C 846
ILE B 656
1.58A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER B  49
ILE A 570
GLY A 552
THR A 559
PHE B 837
1.53A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER C  49
ILE B 570
GLY B 552
THR B 559
PHE B 558
1.25A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
ALA B 732
LEU B 736
LEU B 978
ILE B 975
ILE B 979
LEU B 983
1.80A14.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 13
GLN B 895
PRO A1072
SER A1105
ASN B 896
THR A1099
1.57A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER B  49
ILE A 570
GLY A 552
THR A 559
PHE B 837
1.53A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER A  49
ILE C 570
GLY C 552
THR C 559
PHE C 558
1.55A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER C  49
ILE B 570
GLY B 552
THR B 559
PHE B 558
1.26A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER C  49
ILE B 570
GLY B 552
THR B 559
PHE B 558
1.25A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER A  49
ILE C 570
GLY C 552
THR C 559
PHE C 558
1.42A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
SER B 957
ALA B 954
LEU B 734
ILE B 975
ILE B 979
LEU B 983
1.65A14.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
ILE B 584
ILE B 637
GLY B 638
LEU B 286
PRO B 282
1.57A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs2 ACE2
(Homo
sapiens)		5 / 13
ILE D 307
THR D 371
ILE D 358
MET D 360
THR D 334
1.65A19.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 10
SER C 717
ALA C 753
LEU C 843
GLN B 301
ILE B 299
ILE B 656
1.79A14.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER A  49
ILE C 570
GLY C 552
THR C 559
PHE C 558
1.43A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
ILE C 116
ASN C 189
ILE C  87
GLY C 104
PHE C 130
1.60A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6iex BETA-2-MICROGLOBULIN
(Homo
sapiens)		5 / 13
ILE B   7
PRO B   5
THR B  86
ASN B  83
ILE B  92
1.51A16.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6jyt HELICASE
(SARSr-CoV)		5 / 13
ILE B 488
THR B 547
SER B 513
ASN B 519
THR B 550
1.39A21.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6jyt HELICASE
(SARSr-CoV)		5 / 13
ILE A 488
THR A 547
SER A 513
ASN A 519
THR A 550
1.37A21.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6m17 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		6 / 12
LEU C  86
LEU C  85
LEU C  96
GLN C  94
ILE C 287
LEU C 286
1.75A21.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m17 ACE2
(Homo
sapiens)		5 / 12
MET D 376
ASN D 330
ASP D 355
MET D 323
PHE D 315
1.45A16.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6m17 ACE2
(Homo
sapiens)		5 / 10
THR D 282
SER D 280
LEU D 278
LEU D 248
ILE D 256
1.43A17.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6m17 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
VAL C 505
LEU C  86
ILE C  92
ILE C 287
LEU C 286
1.16A21.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6m17 ACE2
(Homo
sapiens)		6 / 12
SER B 257
ALA B 251
LEU B 281
LEU B 162
PRO B 263
LEU B 262
1.69A17.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6m17 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
VAL A 505
LEU A  86
ILE A  92
ILE A 287
LEU A 286
1.17A21.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m17 ACE2
(Homo
sapiens)		5 / 12
MET B 376
ASN B 330
ASP B 355
MET B 323
PHE B 315
1.45A16.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m17 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
ILE C 407
GLY C 241
THR C 243
LEU C 419
ILE C 236
1.35A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m17 ACE2
(Homo
sapiens)		5 / 12
MET D 383
ILE D 407
GLY D 377
MET D 376
PHE D 356
1.64A16.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6m17 ACE2
(Homo
sapiens)		6 / 12
SER D 257
ALA D 251
LEU D 281
LEU D 162
PRO D 263
LEU D 262
1.69A17.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m17 ACE2
(Homo
sapiens)		5 / 12
MET B 383
ILE B 407
GLY B 377
MET B 376
PHE B 356
1.64A16.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		6m17 ACE2
(Homo
sapiens)		5 / 11
GLU B 181
MET B 474
HIS B 493
ARG B 169
SER B 170
1.80A12.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6m17 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		6 / 12
LEU A  86
LEU A  85
LEU A  96
GLN A  94
ILE A 287
LEU A 286
1.77A21.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		6m17 ACE2
(Homo
sapiens)		5 / 11
GLU D 181
MET D 474
HIS D 493
ARG D 169
SER D 170
1.79A12.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6m17 ACE2
(Homo
sapiens)		5 / 10
THR B 282
SER B 280
LEU B 278
LEU B 248
ILE B 256
1.43A17.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m17 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		6 / 12
SER A 134
ILE A 193
THR A 466
PHE A 123
LEU A 475
ILE A 472
1.75A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m17 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
ILE A 407
GLY A 241
THR A 243
LEU A 419
ILE A 236
1.35A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
GLN A  63
ILE A 251
ILE A 325
GLY A 326
THR A 330
1.22A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		6 / 12
LEU C  86
LEU C  85
LEU C  96
GLN C  94
ILE C 287
LEU C 286
1.67A21.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
ILE C 251
ILE C 325
GLY C 326
THR C 330
GLN C  63
1.23A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
GLN C  63
ILE C 251
ILE C 325
GLY C 326
THR C 330
1.17A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
ILE C 407
GLY C 241
THR C 243
LEU C 419
ILE C 236
1.36A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6m18 ACE2
(Homo
sapiens)		6 / 12
SER D 257
ALA D 251
LEU D 281
LEU D 162
PRO D 263
LEU D 262
1.69A17.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m18 ACE2
(Homo
sapiens)		5 / 13
ILE B 307
THR B 371
ILE B 358
MET B 360
THR B 334
1.66A16.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
VAL A 505
LEU A  86
ILE A  92
ILE A 287
LEU A 286
1.22A21.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m18 ACE2
(Homo
sapiens)		5 / 13
ILE D 307
THR D 371
ILE D 358
MET D 360
THR D 334
1.66A16.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
ILE A 251
ILE A 325
GLY A 326
THR A 330
GLN A  63
1.23A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6m18 ACE2
(Homo
sapiens)		5 / 10
THR D 282
SER D 280
LEU D 278
LEU D 248
ILE D 256
1.39A17.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
GLN C  63
ILE C 251
ILE C 325
GLY C 326
THR C 330
1.22A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
GLN C  94
ILE C 518
SER C 290
ASN C 293
ASP C 302
1.43A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6m18 ACE2
(Homo
sapiens)		5 / 10
THR B 282
SER B 280
LEU B 278
LEU B 248
ILE B 256
1.39A17.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		6 / 12
LEU A  86
LEU A  85
LEU A  96
GLN A  94
ILE A 287
LEU A 286
1.70A21.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
VAL C 505
LEU C  86
ILE C  92
ILE C 287
LEU C 286
1.22A21.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
GLN A  63
ILE A 251
ILE A 325
GLY A 326
THR A 330
1.17A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
ILE A 407
GLY A 241
THR A 243
LEU A 419
ILE A 236
1.36A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6m18 ACE2
(Homo
sapiens)		6 / 12
SER B 257
ALA B 251
LEU B 281
LEU B 162
PRO B 263
LEU B 262
1.71A17.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
GLN A  94
ILE A 518
SER A 290
ASN A 293
ASP A 302
1.43A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
GLN A  63
ILE A 319
ILE A 325
GLY A 326
THR A 330
1.42A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
SER C 278
ILE C  83
GLY C 311
LEU C  80
MET C  71
1.32A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
ILE C 319
ILE C 325
GLY C 326
THR C 330
GLN C  63
1.43A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6m1d ACE2
(Homo
sapiens)		5 / 12
THR D 453
LEU D 456
LEU D 222
ILE D 223
ILE D 513
1.05A17.26
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
SER A 278
ILE A  83
GLY A 311
LEU A  80
MET A  71
1.32A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6m1d ACE2
(Homo
sapiens)		5 / 10
VAL B 573
LEU B 520
PRO B 583
LEU B 584
ILE B 446
1.42A17.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
ILE C  76
PRO C  73
THR C 267
GLY C 272
PHE C  58
1.49A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
SER C 278
ILE C  83
LEU C  80
ILE C  76
MET C  71
1.59A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		6m1d ACE2
(Homo
sapiens)		5 / 11
ASN D 159
LEU D 162
HIS D 493
SER D 692
ILE D 694
1.73A12.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6m1d ACE2
(Homo
sapiens)		5 / 12
THR B 453
LEU B 456
LEU B 222
ILE B 223
ILE B 513
1.05A17.26
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6m1d ACE2
(Homo
sapiens)		5 / 10
VAL D 573
LEU D 520
PRO D 583
LEU D 584
ILE D 446
1.42A17.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m1d ACE2
SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
ILE C 462
MET C 436
PHE C 433
LEU D 760
ILE C 213
1.46A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
ILE A 319
ILE A 325
GLY A 326
THR A 330
GLN A  63
1.44A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
GLN C  63
ILE C 319
ILE C 325
GLY C 326
THR C 330
1.42A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
GLN A  63
ILE A 319
ILE A 325
GLY A 326
THR A 330
1.43A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		6m1d ACE2
(Homo
sapiens)		5 / 11
GLU B 639
ASN B 638
MET D 706
ARG D 708
ILE D 711
1.56A12.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		6m1d ACE2
(Homo
sapiens)		5 / 11
ASN B 159
LEU B 162
HIS B 493
SER B 692
ILE B 694
1.74A12.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
ILE A  76
PRO A  73
THR A 267
GLY A 272
PHE A  58
1.49A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
GLN C  63
ILE C 319
ILE C 325
GLY C 326
THR C 330
1.44A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 13
ILE C 694
PRO B 879
THR B 865
ILE C 687
THR B 869
1.51A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ILE C 694
PRO B 879
THR B 865
ILE C 687
THR B 869
1.50A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
THR B 631
LEU B 597
ILE B 637
LEU B 636
ILE B 674
1.34A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR A 588
SER A 591
SER A 592
VAL A 675
ILE A 584
1.23A14.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
VAL A 990
GLN A 992
ILE B 995
LEU B 994
ILE B 752
1.46A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
ALA C 732
LEU C 736
LEU C 978
ILE C 975
ILE C 979
LEU C 983
1.65A13.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR C 588
SER C 591
SER C 592
VAL C 675
ILE C 584
1.22A14.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
VAL A 860
LEU A1045
ILE A 787
ILE A 800
LEU A 920
LEU A 803
1.77A13.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
GLN C 895
THR A1102
GLY A1075
THR A1087
PHE A1085
1.53A14.72
None
None
None
None
NAG  A1341 (-4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
ALA A 732
LEU A 736
LEU A 978
ILE A 975
ILE A 979
LEU A 983
1.62A13.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6nb7 SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
VAL B 860
LEU B1045
ILE B 787
ILE B 800
LEU B 920
LEU B 803
1.58A13.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6nb7 SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
VAL A 860
LEU A1045
ILE A 787
ILE A 800
LEU A 920
LEU A 803
1.78A13.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6nb7 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
VAL A 990
GLN A 992
ILE B 995
LEU B 994
ILE B 752
1.46A14.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		6nb7 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
LEU C 745
ASN C 721
ARG C 982
SER C 985
LEU C 994
1.67A9.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		6nb8 S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
HEAVY CHAIN
(Homo
sapiens)		5 / 11
ASN H  77
ARG H  72
SER H  71
ILE H  70
LEU H  18
1.78A17.57
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6nur NSP12
(SARSr-CoV)		5 / 12
PHE A 287
LEU A 131
ILE A 244
PRO A 243
MET A 242
1.46A16.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6nur NSP12
(SARSr-CoV)		6 / 12
THR A 913
LEU A 908
LEU A 838
ILE A 837
LEU A 883
LEU A 885
1.80A17.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6nur NSP12
(SARSr-CoV)		5 / 12
GLN A 408
ASN A 543
ILE A 450
GLY A 671
THR A 402
1.25A16.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6nur NSP12
NSP8
(SARSr-CoV)		5 / 12
ASN A 416
ASP A 418
MET D  94
THR D  93
PHE D  92
1.48A16.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6nur NSP12
NSP7
(SARSr-CoV)		5 / 12
SER C  15
ILE A 847
ASP A 846
GLY A 413
PHE A 440
1.61A13.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		6nus NSP12
(SARSr-CoV)		5 / 11
ASN A 790
MET A 633
SER A 692
ILE A 696
LEU A 786
1.79A11.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6nus NSP12
(SARSr-CoV)		6 / 12
ALA A 690
LEU A 638
LEU A 758
ILE A 757
ILE A 589
LEU A 576
1.57A17.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		6nus NSP12
(SARSr-CoV)		5 / 11
GLU A 474
LEU A 469
MET A 633
ILE A 696
LEU A 731
1.72A11.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6nus NSP12
(SARSr-CoV)		5 / 12
PHE A 287
LEU A 131
ILE A 244
PRO A 243
MET A 242
1.45A16.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6vw1 ACE2
(Homo
sapiens)		6 / 10
THR B 282
ALA B 443
LEU B 444
ILE B 436
PRO B 284
ILE B 291
1.71A19.37
None
None
None
NAG  B 714 ( 4.7A)
EDO  B 707 (-4.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vw1 ACE2
(Homo
sapiens)		5 / 12
MET A 383
ILE A 407
GLY A 377
MET A 376
PHE A 356
1.64A19.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vw1 ACE2
(Homo
sapiens)		5 / 12
MET B 383
ILE B 407
GLY B 377
MET B 376
PHE B 356
1.59A19.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6vw1 ACE2
(Homo
sapiens)		5 / 12
THR B 282
SER B 280
VAL B 293
LEU B 440
LEU B 439
1.25A19.20
None
EDO  B 705 ( 3.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6vw1 ACE2
(Homo
sapiens)		6 / 12
SER B 257
ALA B 251
LEU B 281
LEU B 162
PRO B 263
LEU B 262
1.57A19.20
None
None
EDO  B 705 (-4.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6vw1 ACE2
(Homo
sapiens)		6 / 12
SER A 257
ALA A 251
LEU A 281
LEU A 162
PRO A 263
LEU A 262
1.63A19.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vw1 ACE2
(Homo
sapiens)		5 / 12
MET B 383
ILE B 407
GLY B 377
MET B 376
PHE B 356
1.61A19.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6vw1 ACE2
(Homo
sapiens)		5 / 10
THR B 282
SER B 280
LEU B 278
LEU B 248
ILE B 256
1.40A19.37
None
EDO  B 705 ( 3.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		6vw1 ACE2
(Homo
sapiens)		5 / 11
GLU B 181
MET B 474
HIS B 493
ARG B 169
SER B 170
1.77A16.12
None
None
None
CL  B 704 (-4.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6vw1 ACE2
(Homo
sapiens)		6 / 10
THR B 282
LEU B 444
GLN B 598
ILE B 436
PRO B 284
ILE B 291
1.78A19.37
None
None
EDO  B 707 (-3.7A)
NAG  B 714 ( 4.7A)
EDO  B 707 (-4.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6vw1 ACE2
(Homo
sapiens)		5 / 10
THR A 282
SER A 280
LEU A 278
LEU A 248
ILE A 256
1.45A19.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		5 / 12
ILE H  98
GLY H  97
THR H  31
PHE H  29
LEU L  46
1.58A23.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		5 / 12
THR L 178
SER L 176
VAL H 163
LEU H 138
LEU H 141
1.31A20.05
GOL  L 301 (-3.6A)
GOL  L 301 (-3.1A)
None
None
None